Fidelma P. Dunne MD, PhD, FRCP (UK), FRCPICentre for Diabetes, Endocrinology and Metabolism, Galway University Hospital; Diabetes Collaborative Clinical Trials Network, University of Galway; Department of Medicine, College of Medicine, Nursing and Health Science, University of Galway, Galway, Ireland
Fidelma Dunne is a Professor in Medicine at the School of Medicine, National University of Ireland (NUIG), Associate Director of the Clinical Research Facility (CRF) NUI Galway and a Consultant Endocrinologist at Galway University Hospitals group. She holds an MD (University College Cork), PhD (University of Birmingham UK), Masters in Medical Education (University of Dundee Scotland), and Masters in Clinical Research (NUI Galway). She was the Foundation Head of the School of Medicine (2009-2013) and executive board member of Irish Medical Council (2013-2021). Professor Dunne is a member of the Diabetes in Pregnancy Study Group (DPSG) of the EASD and is the past President of the International Association Diabetes in Pregnancy Study Groups (IADPSG) 2016-2022. She was a Fulbright scholar for 2014-2015 at Columbia University New York and is an Adjunct Professor at Steno Diabetes Research Centre in Odense, Denmark (2020-2025).
Her major research interest is in the area of pregnancy and diabetes with >220 peer review publications, 10,000 citations, H index of 53 with >22m euro in grant funding. Her research group are conducting a number of studies as part of the ATLANTIC DIP programme including an IMP regulated RCT of Metformin in pregnancies complicated by GDM (EMERGE), investigation of a biomarker (CD59) for GDM diagnosis and a 10 year follow up (metabolic and cardiovascular) of women with prior GDM. In addition, she has been involved in international studies including a multicentre European funded (FP7) trial on prevention of GDM (DALI), CONCEPTT a JDRF funded trial of continuous glucose monitoring (CGMS) in women with Type 1 Diabetes during pregnancy. More recently she has been the Irish lead for a pan European cohort study examining pregnancy outcomes of women with Type 1 and Type 2 diabetes (EVOLVE) and the EXPECT study examining insulin Degludec (Tresiba) in women with Type 1 Diabetes in pregnancy. She is also the PI of the Health Research Board (HRB) funded national clinical trial network (CTN) in Diabetes.